Clinical Trial Update: To Investigate the Safety and Tolerability of Repeated Subcutaneous Injections of CAD106 in Alzheimer's Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and tolerability of repeated subcutaneous injections of CAD106 in Alzheimer's disease patients has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• CAD106

Snippet

Sponsor: Novartis | Conditions: Alzheimer Disease | Phase 2 | Status: COMPLETED